Clinical Trial Update: Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) [Phase 1, Phase 2]

View source ↗

Summary

An investigator-sponsored Phase 1/2 trial evaluating high-dose ranibizumab for polypoidal choroidal vasculopathy has completed. Results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polypoidal Choroidal Vasculopathy

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Hawaii Pacific Health | Conditions: PCV, Polypoidal Choroidal Vasculopathy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-09-11